glp-1 liver fibrosis Effects of receptor agonists on the degree of and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis For patients with metabolic dysfunction–associated
Description
2024;54(11):e14284
Meier JJ, Gallwitz B, Salmen S, Goetze O, Holst JJ, Schmidt WE, et al
J., Schulte, G., Summers, R
In addition, liraglutide combined with insulin degludec (IDegLira) is a once-daily, fixed dual combination product approved for T2DM
